Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)

Launched by PFIZER'S UPJOHN HAS MERGED WITH MYLAN TO FORM VIATRIS INC. · Feb 28, 2008

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Inclusion criteria:
• • Aged \>=40 years old
• • Diagnosed with OA of the knee according to the American College of Rheumatology and OA in flare state at baseline visit
• • Functional capacity class of I-III
• Exclusion Criteria:
• Exclusion criteria:
• • Inflammatory arthritis or gout or pseudo-gout with acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded)
• • Acute joint trauma at index joint within the past 3 months with active symptoms
• • Score of \>=20 on PHQ-9 or score of \>=1 on PHQ-9 item i
• • Use of mobility assisting device for \<6 weeks or use of walker